Division of Dermatology, Washington University School of Medicine, 660 S. Euclid, Campus Box 8123, St. Louis, MO 63110, USA.
Target Oncol. 2010 Dec;5(4):295-6. doi: 10.1007/s11523-010-0162-5. Epub 2010 Oct 15.
Chemotherapeutic agents targeting the human epidermal receptor (HER) family are being used with increasing frequency for a variety of solid tumors. Cutaneous side effects are commonly reported with HER inhibitors, especially those agents that inhibit epidermal growth factor receptor (EGFR) or HER1. However, inhibitors of HER2 are not associated with specific skin toxicity. We present a case of tufted hair folliculitis, an inflammatory scalp condition causing scaling and pruritus, in a woman being treated with trastuzumab, a selective HER2 inhibitor. This finding has not previously been reported as a side effect of trastuzumab therapy.
针对人表皮受体（HER）家族的化学治疗药物正越来越多地用于各种实体肿瘤。HER 抑制剂常引起皮肤副作用，尤其是那些抑制表皮生长因子受体（EGFR）或 HER1 的药物。然而，HER2 抑制剂与特定的皮肤毒性无关。我们报告了一例簇状毛发滤泡炎，这是一种引起鳞屑和瘙痒的炎症性头皮疾病，发生在接受曲妥珠单抗（一种选择性 HER2 抑制剂）治疗的女性中。这一发现以前尚未被报道为曲妥珠单抗治疗的副作用。
